CohBar’s First Mitochondria Based Therapy Shows Promise In NASH
New Modality In Hard-To-Crack Field
The first clinical results from its mitochondrial derived peptide pipeline is good news for CohBar, but it needs investors or big pharma partners to help it progress.
You may also be interested in...
Novo Nordisk and Gilead Sciences have expanded their clinical collaboration in non-alcoholic steatohepatitis following positive data from a proof-of-concept trial.
CEO Durso says Intercept is aiming to refile its NDA by end of 2021, but several departures in recent months indicate pessimism on NASH prospects to some analysts.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.